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Background: Basophils are important effectors cells in allergic rhinitis (AR) since they are involved in immunoglobulin
(Ig) E – mediated inflammation and in the release of pro-inflammatory mediators. Specific subcutaneous immunotherapy
(SCIT) provides clear immunologic modulation in some immune cells, however its systemic effects on basophils are not
well known.
Methods: Peripheral blood (PB) samples from 43 patients with allergic rhinitis mono-sensitized to Dermatophagoides
pteronyssinus (Dpt) [33 of them under SCIT with allergoid Dpt extract, in maintenance dose (SCIT), with evaluation just
before SCIT injection (SCIT-T0) and 4 hours later (SCIT-T4) and the other 10 Dpt allergic patients never having, in the past,
undergone specific immunotherapy treatment (NSIT)], and 15 healthy age- and gender-matched controls (HG), were
analyzed. For each sample, the total (t-IgE) and specific IgE (s-IgE) was performed, as well as, the relative frequency and
absolute number of PB basophils and receptor-bound IgE and IgG expression were evaluated by flow cytometry and the
Histamine N-methyltransferase (HNMT) and tryptase α/β1 (TPSAB1) gene expression was assessed by real-time PCR.
Results: Higher levels of receptor-bound IgE were observed in SCIT patients, which are correlated with the levels of
serum t-IgE and s-IgE, whereas no significant differences were observed for receptor-bound IgG. Regarding HNMT mRNA
expression, significantly lower expression levels were detected in AR patients compared to HG, independently of type of
therapy. Moreover a negative correlation was found between HNMT gene expression and time under SCIT. Conversely,
tryptase gene expression was significantly up-regulated in NSIT when compared to HG; however in SCIT patients, tryptase
gene expression was significantly decreased than in NSIT patients. No differences were found for any parameter between
SCIT-T0 and SCIT-T4 with exception of a transient increased expression of tryptase in SCIT-T4.
Conclusion: PB basophils from patients with AR show altered functional features, which seems to be influenced by SCIT,
suggesting that these cells could be useful to clarify the SCIT triggered mechanisms at a systemic level.
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Rhinitis is a heterogeneous group of nasal disorders char-
acterized by one or more symptoms, including, sneezing,
itching, rhinorrhea, and/or nasal congestion, which ultim-
ately have a negative impact on the patient’s quality of life.
Rhinitis can be caused by nonallergic factors like infection,
hormones or others [1,2], although approximately 50%
of all cases are allergy-related. This later variant of the
disease - allergic rhinitis (AR) – is the most common
allergic condition affecting 10% to 40% of the world po-
pulation, depending on the geographical setting [3].
Several factors may specifically contribute to the patho-
physiology of AR, including the local synthesis of immuno-
globulin (Ig) E in nasal mucosa, the up-regulation of Th2
cytokines or the alteration in the number of regulatory T
(Treg) cells [4]. However, as an allergic process, most
symptoms arise as a consequence of local inflammation
induced by an IgE-mediated immune response to specific
allergens such as pollens, molds, animal dander and dust
mites [5], ultimately leading to the local accumulation of
an inflammatory cell infiltrate composed of different cells
including T cells, eosinophils, mast cells and basophils
[6,7]. As a result of the cross-linking of IgE on basophils
and mast cells by allergens, several mediators (e.g. leukotri-
enes, prostaglandins, tryptase and histamine) are released
contributing to the development of the inflammatory
response and the symptoms [8].
Basophils along with eosinophils and mast cells, are the
main effector cells in this allergic inflammation process,
but unlike the later cells that reside in the tissue, basophils
circulate in the peripheral blood and selectively migrate to
sites of inflammation [9,10]. Additionally, their active
participation in the pathogenesis of allergic inflammation
has been widely supported in the literature through the
release of preformed and newly generated mediators like
leukotriene C4, major basic protein, IL-4, IL-13, tryptase
and histamine [11-15].
Among these molecules, histamine is the primary me-
diator involved in the development of symptoms of AR in
both early and late-phase reactions, being also able to acti-
vate immunocompetent cells, including T lymphocytes in-
fluencing the Th1/Th2 balance towards a Th2 polarization
[16]. The regulation of the production and activity of this
mediator is performed by its inactivation and/or transport
into cells to remove an excess amount of histamine in
extracellular space. The major routes of histamine in-
activation are catalyzed by two main catabolic pathways:
methylation by oxidative deamination by diamine oxidase
(DAO) and histamine N-methyltransferase (HNMT),
which has been suggested to play a critical role in the
degradation of histamine in the airway [17,18].
Specific subcutaneous immunotherapy (SCIT) has been
widely reported to show clinical effectiveness in the treat-
ment of allergic rhinitis and asthma [19], providing a long-term remission of allergic symptoms and reducing the
development of new sensitization to other allergens
[20,21]. The mechanisms by which clinical responses are
achieved have been extensively described and include a
decrease in basophils and mast cell activation within the
affected tissues, induction of T cells anergy, generation of
Th1 and Treg cells, decrease of allergen-specific IgE anti-
body levels, associated with the production of allergen-
specific IgG1 and IgG4 antibodies (IgG “blocking activity”)
and induction of the production of non-inflammatory IgA
antibodies by B cells [20,22-24].
Interestingly, despite the influence of AR on effector
cells, like basophils, and the impact of SCIT therapy
within the nasal mucosa, are relatively well known, the
potential systemic effect of AR and SCIT on PB baso-
phils remains largely unknown.
In this context, we mainly aimed to evaluate the effects
of AR and SCIT on PB basophils. For this propose we
analyzed the frequency of PB basophils, expression of
receptor-bound IgE and IgG on the membrane and the
mRNA expression of basophil mediator-related genes
(histamine N-methyltransferase and tryptase) in patients
with monosensitization to Dermatophagoides pteronyssinus
(Dpt) submitted to SCIT (before and 4 hours later the
allergen injection) and compared them to AR patients who
were never submitted to SCIT and to healthy individuals.
Moreover we looked for a possible correlation between
those results with total (t-IgE) and specific IgE (s-IgE) in
the serum and with time under SCIT.
Materials and methods
Patients
Overall, 43 AR patients were included in this study, all of
them with at least 2 years of perennial symptoms, wheal
3 mm larger than the negative control related to histamine
response and the values of serum specific IgE at least class
2 (CAP). 33 patients with AR mono-sensitized to mites
under active maintenance SCIT treatment with allergoid
Dpt extract Depigoid (Leti, Madrid, Spain) with monthly
maintenance dose of 0.5 ml volume (Der p 1 = 7.2 μg/ml)
(SCIT) (age: 30 ± 11 years; sex: 19 males and 14 females)
(Table 1). The diagnosis was established based on clinical
symptoms, positive skin prick tests, serum specific IgE
assay, and positive nasal challenge test.
Exclusion criteria included the following: pregnancy,
pediatric group, mental diseases or other comorbidities,
chronic medication and/or active infection and inflam-
mation. At the moment of the treatment implementation
a diagnosis of persistent moderate/severe rhinitis, ARIA
Classification [25], and the presence of concomitant mild
persistent controlled asthma, GINA Classification [26]
was not an exclusion criteria. When included in the study,
all patients presented clinical efficacy to the treatment, as
defined by reduction of clinical score and medication
Table 1 Clinical and laboratorial characteristics of the individuals included in the study
HG NSIT SCIT
(n = 15) (n = 10) (n = 33)
Age (years)
Mean ± SD 29 ± 10 26 ± 7 30 ± 11
Range (18–38) (19–38) (17–61)
Gender
Male 53% (n = 8) 30% (n = 3) 58% (n = 19)
Female 47% (n = 7) 70% (n = 7) 42% (n = 14)
Clinical parameters
Time from disease onset (years) NA 10 ± 7 12 ± 8
Time of SCIT (months) NA NA 28 ± 13
Presence of Asthma NA 40% (4/10) 43% (13/30)
Laboratorial parameters
Serum total IgE (t-IgE) (kU/L) NA 295 ± 231 514 ± 787
Serum specific IgE (s-IgE) (kUA/L) NA 48 ± 27 45 ± 35
NA, Not applies. The results were given by mean ± standard deviation.
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tion (oral anti-histamines). In all of them the induction
phase was achieved after 6 doses of weekly injection,
followed by 1 injection every 4 weeks as a maintenance
dose for a minimum of 12 months. For this particular
group of patients an evaluation before SCIT injection
(SCIT-T0) and 4 hours later (SCIT-T4) was performed,
according the time of the beginning of the late phase of al-
lergen inflammatory response [27].
Additionally, a control group (NSIT) of 10 respiratory
allergic patients monosensitized to mites who had not
submitted, in the past, to specific immunotherapy, and
that displayed the same clinical profile and the exclusion
criteria as the SCIT group (age: 26 ± 7 years; sex: 3
males/7 females) was studied (Table 1). Treatment in
this group of patients was implemented according to the
recommended guidelines (oral systemic anti-histamines,
nasal and bronchial corticosteroid therapy and broncho-
dilators for patients with asthma). Of note, all the ana-
lyses were performed during a period of clinical
stabilization in both AR groups.
Healthy individuals group
Another control group was selected composed by 15
healthy individuals (HG) (age: 29 ± 10 years; sex: 8
males/7 females). These participants were required to
complete a brief questionnaire regarding previous or
current medical conditions. Inclusion criteria for this
group included absence of autoimmune and allergic
diseases, as well as, of an active infection. Additionally,
only individuals who were not undergoing treatment
with immunomodulatory drugs for any known condi-
tions were included in this control group.Samples
PB samples from each individual were collected into K3-
EDTA, serum tubes (Becton Dickinson (BD) Bioscience,
San Jose, CA, USA) and PAXgene Blood RNA tubes
(PreAnalytiX GmbH, Switzerland).
Ethical standards
The study protocol was approved by the Ethical Com-
mittee from Coimbra 185 University Hospital. All partic-
ipants gave and signed an informed consent form, and
the principles of Helsinki Declaration were respected.
Determination of total and specific IgE
Quantitative determination of serum t-IgE was performed
using nephelometry method. Total IgE concentration
(kU/L) was determined comparing the results with the
calibrators provided.
Serum s-IgE to Dermatophagoides pteronyssinus was
determined using the ImmunoCAP fluorescence enzyme
immunoassay technique (Phadia, Uppsala, Sweden). To
evaluate the test results, the response from the patients
samples was converted to concentrations using a cali-
bration curve. The range of measurements was 0.35 to
100 KUA/L.
Multiparameter flow-cytometry immunophenotypic studies
of PB basophils
Identification and characterization of PB basophils was
performed using a anti-IgG conjugated with flourescein
isothiocyanate (clone: G18-145, BD Bioscience), anti- IgE
conjugated with phycoeritrin (clone: BE5, EXBIO Praha,
Vestec, Czech Republic), anti-HLA-DR peridinin chloro-
phyll protein cyanine 5.5 (clone: G46-6, BD Bioscience),
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Biotec; Bergisch, Gladbach, Germany) and anti-CD45
krome orange (clone: J.33, Beckman Coulter, Brea, CA,
USA) combination of monoclonal antibodies (mAb).
For sample processing, two washing steps using
phosphate-buffered saline (PBS) (Gibco BRL-life Tech-
nologies, Vienna, Austria) were performed before staining,
in order to remove the free immunoglobulins present in
the plasma samples. For sample staining, a direct im-
munofluorescence technique was used. Briefly, mAb were
added to 200 μL of PB and were incubated for 15 min at
room temperature in darkness. After this incubation
period, a lyse-and-then-wash protocol was followed: incu-
bation with 2 mL of FACS Lysing Solution (BD Bio-
science) diluted 1:10 (vol/vol) for 10 min followed by a
washing step with 2 mL of PBS (Gibco BRL-life Technolo-
gies). Cells were ressuspended in 0.5 mL of PBS (Gibco
BRL-life Technologies) before acquisition in flow
cytometer.
Flow cytometry data acquisition and analysis
Data acquisition was performed in a FACSCanto II flow
cytometer (BD Bioscience) using the FACSDiva software
(BD Bioscience).
Basophils were identified according to their high expres-
sion of CD123 in absence of HLA-DR and by their moder-
ate CD45 expression, dimmer than lymphocytes [28]. The
relative amount of receptor-bound IgE and IgG was deter-
mined based on their mean fluorescence intensity (MFI).
Absolute numbers were calculated using a dual plat-
form methodology (flow cytometry and hematological
cell analyser). For data analysis the Infinicyt™ software,
V.1.5 (Cytognos SL, Salamanca, Spain) was used.
Gene expression analysis
For the analysis of histamine N-methyltransferase (HNMT)
and tryptase α/β1 (TPSAB1) gene expression, whole per-
ipheral blood was collected in a PAXgene Blood RNATube
(PreAnalytiX) and total automated RNA purification was
performed inQIAcube (Qiagen, Hilden, Germany).
RNA integrity and quantification were performed using
a 6000 Nano Chip® Kit in an Agilent 2100 bioanalyzer
(Agilent, Walbronn, Germany). For quantitative reverse-
transcription polymerase chain reaction (RT-qPCR), one
microgram of RNA was reverse transcribed with iScript™
Reverse Transcription Supermix (Bio-Rad, Hercules, CA,
USA) according to the manufacturer’s instructions.
Relative quantification of gene expression was performed
by real-time PCR using the LightCycler 480 II thermo-
cycler (Roche, Basel, Switzerland). Normalization for gene
expression quantification was performed with a geNorm
Housekeeping Gene Selection Human Kit (Primer Design,
Southampton, UK) and geNorm software (Center for
Medical Genetics, Ghent University Hospital, Ghent,Belgium), in order to select optimal housekeeping genes for
this study [29].
Real-time PCR reactions performed using specific
QuantiTect Primer Assays (Qiagen) with optimized primers
for HNMT (QT00009282) and TPSAB1 (QT01670298) and
endogenous controls as beta-actin (QT01680476) and
glyceraldehyde 3-phosphate dehydrogenase (QT01192646)
with QuantiTect SYBR Green PCR Kit Gene expression
(Qiagen), according to the manufacturer’s instructions.
Reactions were performed with the following thermal
cycling profile: 10 min at 95°C, plus 50 cycles of 10 s at
95°C, 20 s at 55°C, and 30 s at 72°C. Quantitative real-time
PCR results were analyzed with LightCycler 480 software
(Roche) and quantification was performed using the
qBasePlus software package (Biogazelle, Zulte, Belgium).
Statistical analyses
Statistical evaluations of data were performed using the
non-parametric Mann–Whitney U test for independent
variables. Wilcoxon signed-rank test was used to compare
related groups and a Spearman’s rank correlation was
applied to detect the association between different para-
meters. Results were expressed as median with inter-
quartile range. All statistical analyses were performed
using Statistical Package for Social Sciences IBM SPSS 20
(IBM, Armonk, NY. USA) and Graphpad Prism version 5
(GraphPad Software, San Diego, CA, USA). Differences
were considered to be statistically significant when the
p value was less than 0.05.
Results
Relative and absolute quantification of PB basophils
The relative frequency and absolute number of PB
basophils were similar among the four studied groups
(Table 2). Of note, no significant association was found,
both for the frequency and absolute number of PB
basophils with the time under SCIT (data not show).
Serum total and specific IgE levels
Slightly lower total serum IgE (t-IgE) levels were found in
NSIT patients when compared with the SCIT patients,
although not reaching statistical significance. Conversely,
no differences were observed between the two AR groups
regarding serum specific IgE (s-IgE) levels (Table 1).
Expression of receptor-bound IgE and IgG on the
membrane of PB basophils
Receptor-bound IgE expression was significantly in-
creased, and more heterogeneous, in the SCIT patients,
compared with both HG and NSIT (Figure 1a). In line
with this observation, a significant association was found
between serum t-IgE and s-IgE levels and receptor-bound
IgE expression, thus patients with higher serum t-IgE
Table 2 Relative frequency and absolute cell number of circulating peripheral blood basophils in the studied groups
HG NSIT SCIT-T0 SCIT-T4
Relative frequency (%) 0.44 0.40 0.49 0.39
(0.27 – 0.74) (0.25 – 0.67) (0.17 – 0.85) (0.17 – 1.1)
Absolute number (cell/μL) 34 36 41 38
(21 – 70) (17 – 56) (11 – 70) (15 – 97)
Differences were considered statistically significant when p < 0.05. The Mann–Whitney U test used to compare between HG, NSIT, SCIT [evaluation before Dpt
injection (T0) and 4 hours late (T4)]. Wilcoxon signed-rank test was used to compare SCIT-T0 versus the SCIT-T4 group. The results were given by median with
interquartile range.
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bound levels on basophil membrane (Figure 2).
Regarding receptor-bound IgG, no significant differ-
ences were detected among the studied groups, with AR
patients showing expression levels similar to healthy
individuals. Nevertheless, NSIT patients showed a very
heterogeneous distribution, with a slight tendency for a
higher expression compared to both HG and SCIT
(Figure 1b). No differences were found for both receptor-
bound IgE and IgG, comparing SCIT-T0 and SCIT-T4
patients.
Furthermore, a significantly decreased ratio of receptor-
bound IgG and IgE was observed in SCIT patients
compared to NSIT patients, independently of time after
SCIT injection (Table 3).
Histamine N-methyltransferase (HNMT) and tryptase α/β 1
(TPSAB1) gene expression in whole peripheral blood
Overall, AR patients showed significantly lower HNMT
expression levels when compared with healthy controls,
which was more evident in SCIT patients. 4 hours after
SCIT injection the expression of HNMT remains
unchanged (Figure 3a).
Concerning tryptase gene expression significant dif-
ferences were found between groups. Its expression was
increased in NSIT compared to HG. On the other hand,Figure 1 Receptor-bound IgE (a) and IgG (b) on PB basophils. Statistica
U test was used to compare between HG, NSIT, SCIT [evaluation before Dpt in
rank test was used to compare SCIT-T0 versus the SCIT-T4 group. The results w
versus SCIT-T4 , # NSIT versus SCIT-T0, ‡ NSIT versus SCIT-T4.SCIT group showed a significant decreased of tryptase
gene expression than NSIT group (Figure 3b). Despite not
reaching statistical significance, in the SCIT group,
tryptase gene expression showed a tendency to increase
4 hours after SCIT injection.
Effect of treatment on serum total and specific IgE,
receptor-bound IgE and IgG and HNMT and TPSAB1 gene
expression levels according time
HNMT gene expression was negatively correlated
(p = 0.0126) with the time under SCIT. There was a
similar also effect on TPSAB1 gene expression, although
the difference did not reach statistical significance
(Figure 4a, b).
Similarly, serum t-IgE and s-IgE levels had a trend to
decrease over time with SCIT, however it did not reach
statistical significance (Figure 4c, d). Likewise, little
negative correlation and an absence of correlation were
found for receptor-bound IgE and IgG expression over
time with SCIT, respectively (Figure 4e, f ).
Discussion
Specific immunotherapy currently represents the only
treatment that modifies the natural history of allergic rhi-
nitis [27] with proven clinical effectiveness [30]. However,
despite the effects of this treatment being relatively welll significant differences were considered when p < 0.05. Mann–Whitney
jection (T0) and 4 hours later the SCIT infusion (T4)]. Wilcoxon signed-
ere given by median with interquartile range. * HG versus SCIT-T0, § HG
Figure 2 Corelation between receptor-bound IgE and serum t-IgE (a) and s-IgE (b). (a) Positive correlation (rho=0.3923) with statistical
significance (p=0.0112); (b) Absence of correlation (rho=0.2744; p=0.0786). Statistical significant differences were considered when p < 0.05. The
correlations were assessed by the Spearman’s rank correlation.
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a modulation of the T-cell profile, with induction of
allergen-specific Treg cells, that inhibit a proliferative and
cytokine response to the allergen [31,32] or a local
decrease in mast cell and basophil activity [33,34]. The
systemic impact of SCIT in AR patients mono-sensitized
to Dpt, as well as, the repercussion of long-term treatment
on the effector cells of the allergic inflammation, are wide-
spread under research. To address this issue, in this study
we analyzed the frequency and absolute number, the levels
of receptor-bound IgE and IgG and the expression of
mediator-related genes of circulating PB basophils from
AR patients undergoing SCIT and compared them with
both healthy individuals and AR patients who had never
been treated with SCIT.
Overall our results suggest that, contrary to what has
been described for other allergic disorders, like hymenop-
tera allergy [35], AR patients did not show increased PB
basophil numbers. In fact, no significant differences were
found for both relative and absolute basophil frequency
between the different groups included in the study. These
findings are probably reflecting a distinct route of exposure
of the allergen in allergic rhinitis and are in line with previ-
ous studies which reported an increased frequency of
basophils locally, within the airways, in allergic rhinitis
[36,37]. Overall, these results further suggest that, in aller-
gic rhinitis, the high-turnover state of the basophilTable 3 Ratio of receptor-bound IgG and IgE on the
membrane of PB basophils
HG NSIT SCIT-T0 SCIT-T4
Ratio IgG/IgE 2.23 3.50 0.96* 0.98#
(0.56 – 13.57) (1.01 – 8.98) (0.35 – 2.28) (0.17 – 3.81)
Differences were considered statistically significant when p < 0.05. The Mann–
Whitney U test used to compare between HG, NSIT, SCIT [evaluation before
Dpt injection (T0) and 4 hours late (T4)]. Wilcoxon signed-rank test was used
to compare SCIT T0 versus the SCIT T4 group. The results were given by
median with interquartile range.
*SCIT-T0 versus NSIT. #SCIT-T4 versus NSIT.progenitors, resulting the short span of these cells, could
balance their levels in PB circulation [38].
Regarding the amount of receptor-bound IgE on the
basophils surface, increased and more heterogeneous
expression levels were found in the SCIT group com-
pared to both NSIT and HG, which showed a significant
association with serum IgE levels. These observations
are in agreement with previous studies by Kawakami
et al. which reported a relationship between basophil
expression of high-affinity IgE receptor (FcεRI) and
serum IgE levels, as IgE binding to its high affinity re-
ceptor leads to increased expression of FcεRI [23,39-41].
Altogether, these results seem to suggest that, since pa-
tients with higher levels of serum t-IgE and s-IgE
exhibited increased FcεRI-bound IgE expression, the
increased values for receptor-bound IgE observed in
these patients are also reflecting an increased expression
of FcεRI on the basophils membrane. This is in line with
previous studies, which described increased FcεRI
expression in allergic patients [42,43].
Interestingly, both receptor-bound IgE expression and
serum IgE levels were more heterogeneous in SCIT
patients, compared to both HG and NSIT. Since it is
known that allergen-specific immunotherapy leads to an
initial rise, followed by a slow decline, in the level of serum
IgE in allergic patients, during SIT, this high variability
could reflect differences in the time that patients were
undergoing SCIT. In fact, when we analysed the SCIT
effect in the levels of serum t-IgE and receptor-bound IgE
expression, we observed lower levels, for both parameters,
in patients under more time of SCIT [44].
Interestingly, despite it is widely known that allergen-
specific immunotherapy leads to an increase in serum spe-
cific IgG4, similar levels of expression were found for all
the groups included in the study regarding the amount of
receptor-bound IgG on the membrane of PB basophils.
This could probably due to the fact that the anti-IgG anti-
body used to detect bound-IgG also detects other IgG
Figure 3 HNMT (a) and TPSAB1 (b) expression in whole PB. Statistical significant differences were considered when p < 0.05. Mann–Whitney U test
was used to compare between HG, NSIT, SCIT [evaluation before Dpt injection (T0) and after 4 hours (T4)]. Wilcoxon signed-rank test was used to compare
SCIT-T0 versus the SCIT-T4 group. The results were given by median with interquartile range. * HG versus SCIT-T0, § HG versus SCIT-T4 , ∂ HG versus NSIT,
# NSIT versus SCIT-T0.
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bodies for allergen specific IgG and its isotypes, not only
in basophils, but also on other PB cells which express IgG
receptors, to determine whether the increased of IgG4
serum levels are associated with a change in the
membrane-bound IgG4 or other isotypes expression or, as
it has been previously suggested, if the IgG4 pro-
duced during specific immunotherapy does not bind
the effector cells, but protects the patients by bind-
ing the allergen, and therefore preventing its cross-
linking to allergen specific IgE attached to effector
cells or by forming IgG4-allergen-IgE complexes, ul-
timately inhibiting IgE triggering [45].
Remarkably, more than a variation in the isotype (IgE
vs. IgG) or the amount of receptor-bound immuno-
globulin on PB basophils, significant differences were
observed amongst the different study groups regarding
the expression of allergy mediator-related genes. In our
study, AR patients showed significantly lower HNMT
mRNA expression in whole PB, which is in line with
previous studies which reported a decreased expression
of this enzyme in the nasal mucosa [46]. Since no asso-
ciation was found between the frequency of PB baso-
phils and therapy, this seems to indicate, that the
beneficial effects of SCIT on histamine-related symp-
toms could be due not to a variation in the number of
circulating basophils but as a result of histamine lower
production. In line with this, previous studies have also
reported increased expression of histidine decarboxyl-
ase in AR patients nasal mucosa, a key enzyme for the
production of histamine [46], and a decreased hista-
mine release as a result of specific immunotherapy to
hymenoptera venom [47]. A relevant finding in our
study was a negative correlation between time under
SCIT and HNMT gene expression and since the im-
munotherapy could modify the histamine metabolism,
the decrease of HNMT gene expression seems to be an
effect of SCIT.Additionally, histamine metabolism may not be af-
fected directly by allergen-specific immunotherapy, as
reported by Novak et al., in a model of specific venom
immunotherapy, whereas an increase in the expression
of histamine receptor type 2 (H2R) in basophils was ob-
served [48,49]. Furthermore, this imbalance in the ex-
pression of H2R seems to have a suppressive effect in
basophil activity, associated with lower histamine pro-
duction [49,50].
Concerning tryptase, a more apparent modulation
of the gene expression was verified, since a significant
up-regulation in NSIT patients occurs compared both
to healthy group and SCIT patients. This suggests
that SCIT therapy, indeed, leads to a normalization of
the production of this mediator, which is in accord-
ance with previous studies by Klimer et al. who
reported that the higher levels of tryptase in allergic
rhinitis patients appear to be significantly inhibited by
specific immunotherapy [34]. However, upon adminis-
tration of SCIT, a slight increase in the expression of
this mediator is observed, at least 4 hours later. This
observation is in line with the increased expression of
activation-related molecules in PB basophils observed
immediately upon venom immunotherapy [51], and
further supports the generalized recommendation for
a mandatory observation period following each injec-
tion, in order to monitor the patient for the develop-
ment of symptoms of type 1 hypersensitivity reaction
[52]. Despite this increase after 4 hours, in our pa-
tients, SCIT therapy has led to a decrease in the
tryptase mRNA expression. Noteworthy, the expres-
sion of this mast cell and basophil specific mediator,
could be the result of a decrease in the release of
basophil mediators [35], this decrease probably re-
flects the generation of allergen-specific Treg cells
that are able to produce anti-inflammatory cytokines
like IL-10 [33], known to reduce basophil responsive-
ness to IgE-mediated stimuli, through the down-
Figure 4 Correlation between analytical parameters and time under SCIT. (a) Negative correlation between HNMT expression and time under
SCIT (rho=-0.4820; p=0.0126). Absence of correlation between time under SCIT and TPSAB1 expression (b), serum t-IgE levels (c), serum s-IgE levels (d),
receptor-bounded IgE (e) and receptor-bounded IgG (f). Statistical significant differences were considered when p < 0.05. Correlations were assessed
by the Spearman’s rank correlation. The evaluation was performed in SCIT patients before SCIT injection.
Lopes et al. Allergy, Asthma & Clinical Immunology 2013, 9:40 Page 8 of 10
http://www.aacijournal.com/content/9/1/40regulation of the expression of key IgE signalling
molecules [53].
Conclusion
In summary, we showed that in AR patients under SCIT,
peripheral blood basophils are functionally altered, with an
increase of the receptor-bound IgE expression which ispositively correlated with serum t-IgE and a decrease in
HNMT and tryptase gene expression, when compared to
AR patients never underwent specific immunotherapy.
Moreover a significant negative correlation between HNMT
gene expression and time under therapy was observed.
Overall, these findings seem to contribute to a better
definition of the SCIT triggered mechanisms in circulating
Lopes et al. Allergy, Asthma & Clinical Immunology 2013, 9:40 Page 9 of 10
http://www.aacijournal.com/content/9/1/40basophils. However further studies, in a larger cohort of
patients, would be necessary to determine the exact role
that SCIT therapy could have on these parameters.
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